Analytical Data
-
Gene name
KIR2DS1
- Application
-
Alternative Names
CD158 antigen-like family member HMHC class I NK cell receptor Eb6 ActI; CD158h
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q14954
-
Expression Region
22-245aa
-
Molecular Weight
26.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KIR2DS1 (Killer Immunoglobulin-like Receptor 2DS1) is a member of the KIR (Killer Immunoglobulin-like Receptor) family, which plays a crucial role in the immune system, particularly in the regulation of natural killer (NK) cells. This receptor is involved in the recognition of target cells, modulating the immune response against tumors and viral infections. Unlike its inhibitory counterparts, KIR2DS1 is an activating receptor, meaning it can trigger immune activation when it binds to specific ligands. Research into KIR2DS1 recombinant proteins has gained momentum due to its potential implications in cancer immunotherapy and transplantation. Understanding the structural and functional characteristics of KIR2DS1 can provide insights into how NK cells discriminate between healthy and malignant cells, ultimately advancing therapeutic strategies that harness the body’s immune response. Furthermore, KIR2DS1 has been associated with improved outcomes in certain cancers, making it a target of interest for developing novel immunomodulatory agents. By studying KIR2DS1 and its interactions at the molecular level, researchers aim to elucidate its role in immune regulation and refine approaches for enhancing NK cell activity in clinical settings, paving the way for better prognostic tools and treatments in oncology and beyond.
